38275-49-9 Usage
Uses
Used in Pharmaceutical Industry:
Methyl 2-methanesulfonylpyrimidine-5-carboxylate is used as a building block in organic synthesis for the preparation of pharmaceuticals. Its unique structure allows for the development of new drugs with potential therapeutic applications.
Used in Agrochemical Industry:
Methyl 2-methanesulfonylpyrimidine-5-carboxylate is also used as a building block in the synthesis of agrochemicals. Its versatility in organic synthesis enables the creation of new compounds with potential applications in agriculture.
Used in Antiviral Research:
Methyl 2-methanesulfonylpyrimidine-5-carboxylate has been studied for its potential antiviral properties. Its unique structure may contribute to the development of new antiviral agents.
Used in Anticancer Research:
Methyl 2-methanesulfonylpyrimidine-5-carboxylate has also been investigated for its potential anticancer properties. Its unique chemical structure may offer new avenues for cancer treatment and research.
Overall, Methyl 2-methanesulfonylpyrimidine-5-carboxylate is a significant chemical in the fields of medicinal and synthetic chemistry due to its various practical applications and potential biological activities.
Check Digit Verification of cas no
The CAS Registry Mumber 38275-49-9 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 3,8,2,7 and 5 respectively; the second part has 2 digits, 4 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 38275-49:
(7*3)+(6*8)+(5*2)+(4*7)+(3*5)+(2*4)+(1*9)=139
139 % 10 = 9
So 38275-49-9 is a valid CAS Registry Number.
38275-49-9Relevant academic research and scientific papers
PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS
-
Page/Page column 91-92; 99, (2008/12/04)
This invention is directed to a compound wherein R1, R2, R3, R4 and L1 are as defined herein, a pharmaceutical composition comprising the compound, and the use of the compound to treat allergic and/or
PYRIMIDINE AMIDE COMPOUNDS AS PGDS INHIBITORS
-
Page/Page column 67, (2010/11/26)
This invention is directed to a compound of formula (I): wherein R1, R2, R3 and L1 are as defined herein, a pharmaceutical composition comprising the compound, and the use of the compound to treat allergic and/or inflammatory disorders, particularly disorders such as allergic rhinitis, asthma and/or chronic obstructive pulmonary disease (COPD).
FUSED HETEROCYCLIC COMPOUNDS USEFUL AS INHIBITORS OF HISTONE DEACETYLASE
-
Page/Page column 92, (2008/06/13)
Disclosed are compounds of formula (I) that inhibit histone deacetylase (HDAC) enzymatic activity, pharmaceutical compositions comprising such compounds, as well as methods to treat conditions, particularly proliferative conditions, mediated at least in part by HDAC, wherein A, W, W1, W2, Ar2, and G are described herein.
